Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain

Add time:07/27/2019    Source:sciencedirect.com

N-type calcium channel blockade is a promising therapeutic approach for the treatment of neuropathic pain. Starting from lead compound (S)-1, we focused our optimization efforts on potency for N-type calcium channel inhibition and improvement of CYP inhibition profile. 2-{[(1-Hydroxycyclohexyl)methyl]amino}-(1R)-(1-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethanone oxalate ((R)-5r) was identified as a novel orally active small-molecule N-type calcium channel inhibitor with reduced CYP inhibition liability. Oral administration of (R)-5r improved mechanical allodynia in a spinal nerve ligation model of neuropathic pain in rats with an ED50 value of 2.5 mg/kg.

We also recommend Trading Suppliers and Manufacturers of 1-(Hydroxycyclohexyl)-(4-methoxyphenyl)acetonitrile (cas 131801-69-9). Pls Click Website Link as below: cas 131801-69-9 suppliers

Prev:Development of a novel radiobromine-labeled sigma-1 receptor imaging probe
Next:7-alkoxyquinolines: New fluorescent substrates for cytochrome p450 monooxygenases)